Safety concerns rise as Neurocrine's rare-disease drug linked to multiple deaths
Patient groups and some experts are alarmed after Vykat XR, approved for Prader-Willi syndrome, has been associated with seven deaths and nearly 100 hospitalizations.
Two months after an open letter highlighted possible safety problems with Neurocrine Biosciences' drug Vykat XR, advocates and certain specialists are voicing heightened worry. The medication, cleared for Prader-Willi syndrome, has been tied to seven fatalities and close to a hundred hospital admissions since its approval 18 months ago. Regulatory case reports obtained via FOIA show complex medical histories and multiple concurrent drugs, but some experts argue the pattern indicates unacceptable risk.
Why it matters
The story highlights possible serious risks of a newly approved rare-disease drug, affecting patients and prompting regulatory scrutiny.
In this story
